SCHEMBL2194152

SCHEMBL2194152

CCOC(=O)c1cc(-c2cccc(C(F)(F)F)c2)n(-c2cccc(Cl)c2)n1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.54
NPY5R Q15761 2/20 0.52
LMNA P02545 2/20 0.52
TP53 P04637 1/20 0.52
CHRNA7 P36544 3/20 0.51
MGLL Q99685 2/20 0.50
CA9 Q16790 1/20 0.50
GABRA2 P47869 1/20 0.50
GABRB2 P47870 1/20 0.50
ALDH1A1 P00352 1/20 0.48
PPP1CA P62136 1/20 0.48
MAPT P10636 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
SLC5A1 P13866 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1764964 0.97 FAAH (0.53) FAAHNPY5RLMNATP53CHRNA7
SCHEMBL1765057 0.93 LMNA (0.52) FAAHNPY5RLMNATP53CHRNA7
SCHEMBL1764938 0.92 CHRNA7 (0.61) FAAHLMNATP53CHRNA7MGLL
SCHEMBL1764943 0.91 FAAH (0.53) FAAHNPY5RCHRNA7MGLLCA9
SCHEMBL1764934 0.90 LMNA (0.59) FAAHLMNATP53CHRNA7MGLL
SCHEMBL1765268 0.89 LMNA (0.49) FAAHNPY5RLMNATP53CHRNA7
SCHEMBL2192072 0.89 FAAH (0.57) FAAHNPY5RTP53CHRNA7MGLL
SCHEMBL2193609 0.88 FAAH (0.60) FAAHCHRNA7MGLLCA9MAPT
SCHEMBL1765482 0.87 FAAH (0.56) FAAHLMNATP53CHRNA7MGLL
SCHEMBL1764945 0.87 CHRNA7 (0.62) FAAHCHRNA7MGLLCA9GABRA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2278965-B1 SUBSTITUTED PYRAZOLAMIDES AND THE USE THEREOF AICURIS GMBH & CO KG (DE) 2013-11-13 EP disclosed
US-8314089-B2 Substituted pyrazolamides and their use AICURIS GMBH & CO. KG (DE) 2012-11-20 US disclosed
US-8314089-B2 Substituted pyrazolamides and their use AICURIS GMBH & CO. KG (DE) 2012-11-20 US disclosed
US-20110172207-A1 SUBSTITUTED PYRAZOLAMIDES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-07-14 US disclosed
US-20110172207-A1 SUBSTITUTED PYRAZOLAMIDES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-07-14 US disclosed
US-20110172207-A1 SUBSTITUTED PYRAZOLAMIDES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-07-14 US disclosed
WO-2009115252-A2 SUBSTITUTED PYRAZOLAMIDES AND THE USE THEREOF AICURIS GMBH & CO. KG (DE) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172207-A1 SUBSTITUTED PYRAZOLAMIDES AND THEIR USE CACNA1A, P2RX4, KCNH1 FAAH 1131/4885NPY5R 1170/4885LMNA 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.